Editas Medicine

#NEWS: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates. For more details, read the full press release here: bit.ly/4stTz8X #biotech #geneediting #earnings

#News: Editas Medicine to Participate in Upcoming Investor Conferences. For more details, read the full press release here: bit.ly/46oArAO #invivogeneediting #biotechnology #healthcare

Gilmore O’Neill joined the Let's Talk About That podcast to discuss the future of in vivo gene editing and EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved ≥90% mean LDL cholesterol reduction in NHPs. Listen here: bit.ly/4k3RHko

#NEWS: Editas Medicine Announces Third Quarter 2025 Results and Business Updates. For more details, read the full press release here: bit.ly/43XeZ4z #biotech #earnings

#NEWS: Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025. For more details, read the full press release here: bit.ly/4qUoXh8 #geneediting #biotech

#NEWS: Editas Medicine Reports In Vivo Proof-Of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress: bit.ly/4q7HKoM #invivogeneediting #geneediting

#NEWS: Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences. For more details, read the full press release here: bit.ly/4o9XqpO #geneediting

#NEWS: Editas Medicine Nominates EDIT-401, an experimental, LDLR-Targeted Medicine, as Lead In Vivo Development Candidate. For more details, read the full press release here: bit.ly/46iYIs8 #invivogeneediting #geneediting #Biotechnology

#News: Editas Medicine to host webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET announcing the selection of its lead in vivo development candidate. For more details, read the full press release here: bit.ly/3Jw3Z77 #invivogeneediting #crispr #biotechnology

#News: Editas Medicine to Participate in Upcoming Investor Conferences. For more details, read the full press release here: [bit.ly/4g6ayt5] #invivogeneediting #biotechnology #healthcare

#News: Editas Medicine Announces Second Quarter 2025 Results and Business Updates. Read the press release for details: [ bit.ly/4mhovH0 ] #invivogeneediting #geneediting #Biotechnology

#News: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at #EHA2025: Read the press release at bit.ly/3ZupBps #hematology #invivogeneediting

We’re at the #TIDESUSA 2025 Meeting. Over the next week, we’ll be presenting preclinical data to support our development of transformative in vivo gene editing medicines. For presentation information, visit the TIDES agenda: bit.ly/3Eni0g2 #invivogeneediting #geneediting

In her PharmaVoice interview, CFO Amy Parison shares her perspective on joining Editas as we focus on in vivo gene editing. Her approach reflects the clarity and discipline guiding our next chapter. #GeneEditing #InVivoGeneEditing Full interview: bit.ly/3SGKRnU

Next week we’ll be participating in the #TIDESUSA 2025 Meeting. Learn more: bit.ly/3Eni0g2 #invivogeneediting #geneediting #Biotechnology

Attending #ASGCT2025? Check out our posters AMA640 and AMA351 featured during the Wednesday Poster Reception from 5:30 p.m. – 7:00 p.m. CT in Hall 12 or you can view them online here: bit.ly/3wR3jht #invivogeneediting #geneediting #Biotechnology

Join us today in Room 265-268, from 1:30-1:45 p.m. for our oral presentation, “In Vivo Delivery of HBG1/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-Human Primate with Lipid Nanoparticle”, at #ASGCT2025. #invivogeneediting #geneediting #Biotechnology

Good morning from #ASGCT2025! Today we are presenting pre-clinical data to support our development of transformative in vivo gene editing medicines. For presentation information, visit bit.ly/3REdwK0 #invivogeneediting #geneediting #Biotechnology

#News: Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data European Hematology Association 2025 Congress in June. Read the press release for details: bit.ly/4kjOQmn @EHA_Hematology #EHA2025

#News: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting. Read the press release for details: bit.ly/4mhHnGc #ASGCT2025 #invivogeneediting